PharmaTelevision - Peter York and Paul Thorning of CrystecPharma explain why they have chosen to base their operations in China

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Peter York and Paul Thorning of CrystecPharma explain why they have chosen to base their operations in China

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Peter York & Paul Thorning from CrystecPharma.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Super Critical Fluid (SCF) technology: Importance and potential applications in Pharmaceutical industry

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Oxford in the UK. On this show I have Professor Peter York, who is Emeritus Professor of Physical Pharmaceutics at Bradford University and Paul Thorning, who is the CEO of the company we are gonna talk about which is called Crystec and of course Peter you are also the Chairman and Chief Scientific Officer of Crystec. Now Peter you have a history of innovation and founding companies and so forth and you are involved in yet another one, the other theme is the area of super-critical fluid (SCF) Technology, so before we start to talk about Crystec itself specifically could you just give us, give our audience a taste of why SCF technology is so important and its potential application to the pharmaceutical industry?

Peter York:

Yes I am pleased too, in fact the initial phase of my interest in super-critical fluids came as a result of chatting with colleagues in the pharmaceutical industry who bemoaning the use of the technologies that were available for producing fine particles those increasing interest in the pharmaceutical industrial in fine particles lot to overcome some of the current challenges that exist with both small molecules and macromolecules in moving them efficiently into efficacious medicine, current techniques for making fine particles were limited they led to some distress, difficulty, and secondary processing and so on, so I went away thinking about an alternative way of making particles and into the literature talking around came up with the experience of some success quite early on using super-critical fluids this process lends itself to great versatility and variety and the ability to design particles drug particles and in many cases overcome some of the challenges the industry were facing with the current technologies for preparing small particles of these API's.

Fintan Walton:

Okay, so it overcomes a number of problems that the industry is presented with obviously particle size is one, the other is composition, I think there is more?

Peter York:

Well there is a whole series of wishes behind the design of these particles not only in terms of the processing and formulation but also moving to regulatory issues and manufacturing issues, stability issues and it's the features that are desirable in the design of that particle it might be size, it might be shape, may be composition, it may be purity, it may be residual solvent levels, it may be handling problems downstream, it may be changing the release profile to modulate the release and absorption of drugs, these are features that are able to be engineered into the design of particles because of this rather wonderful approach that's based on super-critical fluid technologies.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Peter York

Chairman

At the time of this PTV interview, Professor Peter York is Chairman and a co-founder of CrystecPharma and is also Chief Scientist with responsibility for guiding the overall science and innovation strategy of the company. He is an Emeritus Professor of Physical Pharmaceutics and a world leading expert in pharmaceutical materials science. He has published over 300 scientific articles, holds numerous patents, and has received several research awards. He was the founder of Bradford Particle Design Ltd , a spinout venture from the University of Bradford , based on research and patents in particle formation by supercritical fluids, which was acquired for $200m by Inhale Therapeutics in 2001. He holds Fellowships of the Royal Pharmaceutical Society of Great Britain, the Royal Society of Chemistry, and the American Association of Pharmaceutical Scientists. He sits on MHRA and EMEA drug review panels and is a member of British Pharmacopoeia Commission. He is an Honorary Visiting Professor of the Shanghai Institute of Materia Medica, Chinese Academy of Science.

Paul Thorning

CEO

Paul Thorning is a co-founder of CrystecPharma and is Chief Executive Officer with overall strategic management responsibility for the company. He has over 20 years experience in the chemical and pharmaceutical industries in manufacturing, research, marketing, consultancy and senior executive roles. In his role as Director of the Institute of Pharmaceutical Innovation at the Bradford University, he has been actively involved in innovation in pharmaceutical sciences including the establishment of 3 innovation-based companies over the past 7 years. Away from the pharmaceutical industry, Paul spent three years in Tanzania, Africa, where he was responsible for a team running hospitals, health programmes and community services for 140,000 Congolese refugees. Paul is on the board of two other healthcare-related companies, is a Non-Executive Director of Medilink Yorkshire, and a member of the UK-China Joint Economic Trade Commission Healthcare Working Group. Paul speaks English, French, Italian and Swahili (and very basic Mandarin), holds an MBA and professional membership of the Institute of Marketing, and is a Fellow of the Institution of Mechanical Engineers.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

CrystecPharma

CrystecPharma is based in Bradford, United Kingdom, with a wholly owned subsidiary research company based in Tianjin, China. CrystecPharma engages in contract and collaborative research, as well as licensing proprietary technology and intellectual property in solid state pharmaceutical materials. The CrystecPharma team consists of the some of the world's most well known scientists in the field, including Peter York (co-founder of Bradford Particle Design ), Lyn Daintree and George Townend. Combined the team has over 50 years experience in super-critical fluid technology in pharmaceutical particle engineering. CrystecPharma are committed to excellence in science and innovation, operating to the highest standards of customer service, professionalism, integrity and employment.

CrystecPharma